179 related articles for article (PubMed ID: 9405231)
1. Evaluation of anti-hepatitis B virus (HBV) drugs using the HBV transgenic mouse: application of the semiquantitative polymerase chain reaction (PCR) for serum HBV DNA to monitor the drug efficacy.
Kajino K; Kamiya N; Yuasa S; Takahara T; Sakurai J; Yamamura Ki; Hino O
Biochem Biophys Res Commun; 1997 Dec; 241(1):43-8. PubMed ID: 9405231
[TBL] [Abstract][Full Text] [Related]
2. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
3. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus.
Julander JG; Sidwell RW; Morrey JD
Antiviral Res; 2002 Jul; 55(1):27-40. PubMed ID: 12076749
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
6. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
[TBL] [Abstract][Full Text] [Related]
7. Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine.
Morrey JD; Bailey KW; Korba BE; Sidwell RW
Antiviral Res; 1999 Jun; 42(2):97-108. PubMed ID: 10389653
[TBL] [Abstract][Full Text] [Related]
8. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
9. Anti-hepatitis B virus activity of wogonin in vitro and in vivo.
Guo Q; Zhao L; You Q; Yang Y; Gu H; Song G; Lu N; Xin J
Antiviral Res; 2007 Apr; 74(1):16-24. PubMed ID: 17280723
[TBL] [Abstract][Full Text] [Related]
10. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
[TBL] [Abstract][Full Text] [Related]
11. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation.
Mutimer D; Pillay D; Dragon E; Tang H; Ahmed M; O'Donnell K; Shaw J; Burroughs N; Rand D; Cane P; Martin B; Buchan S; Boxall E; Barmat S; Gutekunst K; McMaster P; Elias E
J Hepatol; 1999 Apr; 30(4):715-21. PubMed ID: 10207815
[TBL] [Abstract][Full Text] [Related]
12. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma.
Allice T; Cerutti F; Pittaluga F; Varetto S; Gabella S; Marzano A; Franchello A; Colucci G; Ghisetti V
J Clin Microbiol; 2007 Mar; 45(3):828-34. PubMed ID: 17229858
[TBL] [Abstract][Full Text] [Related]
13. Transgenic mice as a chemotherapeutic model for hepatitis B virus infection.
Morrey JD; Korba BE; Sidwell RW
Antivir Ther; 1998; 3(Suppl 3):59-68. PubMed ID: 10726056
[TBL] [Abstract][Full Text] [Related]
14. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents.
Ilan E; Burakova T; Dagan S; Nussbaum O; Lubin I; Eren R; Ben-Moshe O; Arazi J; Berr S; Neville L; Yuen L; Mansour TS; Gillard J; Eid A; Jurim O; Shouval D; Reisner Y; Galun E
Hepatology; 1999 Feb; 29(2):553-62. PubMed ID: 9918935
[TBL] [Abstract][Full Text] [Related]
15. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
Lu H; Ma LX; Xu WS; Zhang HY; Yu LJ; Duan HY
Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Alvarez-Uria G; Ratcliffe L; Vilar J
HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
[TBL] [Abstract][Full Text] [Related]
18. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
Yaşar DG; Suyanı E; Özenirler S; Sucak GT
Transplant Proc; 2013 Mar; 45(2):833-4. PubMed ID: 23498831
[TBL] [Abstract][Full Text] [Related]
19. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
Wiegand J; Wedemeyer H; Finger A; Heidrich B; Rosenau J; Michel G; Bock CT; Manns MP; Tillmann HL
Antivir Ther; 2008; 13(4):547-54. PubMed ID: 18672533
[TBL] [Abstract][Full Text] [Related]
20. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
Nebbia G; Garcia-Diaz A; Ayliffe U; Smith C; Dervisevic S; Johnson M; Gilson R; Tedder R; Geretti AM
J Med Virol; 2007 Oct; 79(10):1464-71. PubMed ID: 17705185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
